Comments
Loading...

Inovio Pharmaceuticals Analyst Ratings

INONASDAQ
Logo brought to you by Benzinga Data
$1.92
-0.02-1.03%
At close: -
$1.98
0.063.13%
After Hours: 7:59 PM EDT
Q1 2025 Earnings were released on Tue May 13th, after the market close
The most recent conference call was at 16:30 PM, 1 day ago Click to view past webcast
Consensus Rating1
Market Outperform
Highest Price Target1
$40.00
Lowest Price Target1
$2.00
Consensus Price Target1
$15.13

Inovio Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:INO | Benzinga

Inovio Pharmaceuticals Inc has a consensus price target of $15.13 based on the ratings of 9 analysts. The high is $40 issued by Oppenheimer on March 8, 2024. The low is $2 issued by B of A Securities on November 1, 2022. The 3 most-recent analyst ratings were released by RBC Capital, HC Wainwright & Co., and Citizens Capital Markets on March 19, 2025, March 19, 2025, and March 14, 2025, respectively. With an average price target of $8.67 between RBC Capital, HC Wainwright & Co., and Citizens Capital Markets, there's an implied 337.71% upside for Inovio Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
1
Nov 24
1
Jan
1
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.3
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

RBC Capital
HC Wainwright & Co.
Citizens Capital Markets
JMP Securities
Oppenheimer

1calculated from analyst ratings

Analyst Ratings for Inovio Pharmaceuticals

Buy NowGet Alert
03/19/2025Buy Now152.53%RBC Capital
Gregory Renza47%
$6 → $5MaintainsSector PerformGet Alert
03/19/2025Buy Now51.52%HC Wainwright & Co.
Raghuram Selvaraju43%
$3 → $3ReiteratesNeutral → NeutralGet Alert
03/14/2025Buy Now809.09%Citizens Capital Markets
Roy Buchanan36%
$18 → $18ReiteratesMarket Outperform → Market OutperformGet Alert
01/13/2025Buy Now51.52%HC Wainwright & Co.
Raghuram Selvaraju43%
$5 → $3MaintainsNeutralGet Alert
01/10/2025Buy Now809.09%JMP Securities
Roy Buchanan36%
$18 → $18ReiteratesMarket Outperform → Market OutperformGet Alert
11/18/2024Buy Now152.53%HC Wainwright & Co.
Raghuram Selvaraju43%
$12 → $5MaintainsNeutralGet Alert
11/18/2024Buy Now657.58%Oppenheimer
Jay Olson60%
$33 → $15MaintainsOutperformGet Alert
11/15/2024Buy Now203.03%RBC Capital
Gregory Renza47%
$7 → $6MaintainsSector PerformGet Alert
10/04/2024Buy Now253.54%RBC Capital
Gregory Renza47%
$8 → $7MaintainsSector PerformGet Alert
08/12/2024Buy Now1566.67%Oppenheimer
Jay Olson60%
$40 → $33MaintainsOutperformGet Alert
08/09/2024Buy Now304.04%RBC Capital
Gregory Renza47%
$11 → $8MaintainsSector PerformGet Alert
07/15/2024Buy Now657.58%HC Wainwright & Co.
Raghuram Selvaraju43%
$15 → $15ReiteratesNeutral → NeutralGet Alert
05/14/2024Buy Now910.1%Stephens & Co.
Sudan Loganathan30%
→ $20Initiates → OverweightGet Alert
03/08/2024Buy Now1920.2%Oppenheimer
Hartaj Singh45%
$40 → $40MaintainsOutperformGet Alert
03/07/2024Buy Now455.56%RBC Capital
Gregory Renza47%
→ $11ReiteratesSector Perform → Sector PerformGet Alert
01/25/2024Buy Now102.02%Oppenheimer
Hartaj Singh45%
→ $4UpgradePerform → OutperformGet Alert
01/04/2024Buy Now-49.49%JMP Securities
Roy Buchanan36%
→ $1Initiates → Market OutperformGet Alert
05/11/2023Buy Now1.01%RBC Capital
Gregory Renza47%
→ $2ReiteratesSector Perform → Sector PerformGet Alert
03/02/2023Buy Now1.01%RBC Capital
Gregory Renza47%
$3 → $2MaintainsSector PerformGet Alert
11/09/2022Buy Now—Maxim Group
Jason McCarthy41%
—DowngradeBuy → HoldGet Alert
11/01/2022Buy Now1.01%B of A Securities
Geoff Meacham60%
→ $2DowngradeNeutral → UnderperformGet Alert
08/10/2022Buy Now51.52%RBC Capital
Gregory Renza47%
$4 → $3MaintainsSector PerformGet Alert

FAQ

Q

What is the target price for Inovio Pharmaceuticals (INO) stock?

A

The latest price target for Inovio Pharmaceuticals (NASDAQ:INO) was reported by RBC Capital on March 19, 2025. The analyst firm set a price target for $5.00 expecting INO to rise to within 12 months (a possible 152.53% upside). 12 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Inovio Pharmaceuticals (INO)?

A

The latest analyst rating for Inovio Pharmaceuticals (NASDAQ:INO) was provided by RBC Capital, and Inovio Pharmaceuticals maintained their sector perform rating.

Q

When was the last upgrade for Inovio Pharmaceuticals (INO)?

A

The last upgrade for Inovio Pharmaceuticals Inc happened on January 25, 2024 when Oppenheimer raised their price target to $4. Oppenheimer previously had a perform for Inovio Pharmaceuticals Inc.

Q

When was the last downgrade for Inovio Pharmaceuticals (INO)?

A

The last downgrade for Inovio Pharmaceuticals Inc happened on November 9, 2022 when Maxim Group changed their price target from N/A to N/A for Inovio Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Inovio Pharmaceuticals (INO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inovio Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inovio Pharmaceuticals was filed on March 19, 2025 so you should expect the next rating to be made available sometime around March 19, 2026.

Q

Is the Analyst Rating Inovio Pharmaceuticals (INO) correct?

A

While ratings are subjective and will change, the latest Inovio Pharmaceuticals (INO) rating was a maintained with a price target of $6.00 to $5.00. The current price Inovio Pharmaceuticals (INO) is trading at is $1.98, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch